Tag Archives: Prosensa

  1. Cure Duchenne Has Funded All Types of Duchenne Research

    Posted on September 23, 20145:15 pm

    CureDuchenne is proud to have supported all types of Duchenne research over the past 10 years. That is why CureDuchenne has been a leader in funding exon skipping, stop codon, rare and duplications mutations, utrophin upregulation as well as anti-fibrotic and anti-inflammatory therapies during the past decade. Click here for full image. CureDuchenne’s focus is Read more »

  2. Prosensa Update About Drisapersen & Other Programs Webinar

    Posted on September 22, 20149:24 pm

    UPPMD is hosting a Prosensa Update About Drisapersen & Other Programs webinar on behalf of all of its member organizations worldwide.   Date and Time:  Thursday October 2nd 2014 at 6pm CET (noon Eastern and 9 a.m. Pacific) Speakers:  The webinar will be presented by Anthony Hall MD, Medical Director Medical Affairs of Prosensa and he will Read more »

  3. Prosensa announces commencement of re-dosing of drisapersen in North America in patients with Duchenne muscular dystrophy

    Posted on September 17, 20147:27 pm

    CureDuchenne is delighted to share that Prosensa has begun re-dosing patients. See below for today’s announcement.  We are happy that CureDuchenne funding is helping to move Prosensa’s exon skipping programs forward. Our $7 million collaboration with Prosensa is helping to accelerate access to exon skipping drugs for several mutations for patients who so desperately need it. Read more »


    Posted on September 7, 20143:53 pm

    Your dollar can save lives… CureDuchenne is pleased to launch the “Dollar 4 Duchenne” campaign today to fund research to find a cure for Duchenne muscular dystrophy.  The “Dollar 4 Duchenne” campaign encourages people to donate one dollar to help fund Duchenne research.  “Dollar 4 Duchenne” is part of a comprehensive CureDuchenne fundraising campaign to Read more »

  5. Sarepta and Prosensa Announcements This Week

    Posted on August 8, 20134:40 pm

    There continues to be good news for the Duchenne community.  We will continue to monitor Duchenne research news and share it with you as it becomes available. Here are three announcements from this week: Sarepta Therapeutics Announces Publication of Eteplirsen Clinical Study Results in the Annals of Neurology Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer Read more »

  6. Drisapersen, Etiplersen, GSK, Prosensa and Sarepta, a Positive Week for Duchenne

    Posted on April 11, 201311:09 pm

    Thanks to GSK, Prosensa and Sarepta and, the landscape is changing for the patients and families that are suffering from Duchenne, a severe muscle disease that shortens the life expectancy and quality of life for approximately 300,000 boys and young men worldwide. Even though these potential treatments that are currently in the news have not Read more »

  7. CureDuchenne – Clinical Trials – FDA

    Posted on December 7, 201212:45 am

    Following the long awaited news of Sarepta’s phase IIB results for eteplirsen and continued Phase III progress of GSK/Prosensa’s drisapersen, as well as the recent developments with PTC Therapeutics and Summit PLC among others, CureDuchenne took the initiative to reach out for patients and advocacy groups alike to begin a dialogue with the FDA and Read more »